Literature DB >> 22123262

Type A1 but not type A2 botulinum toxin decreases the grip strength of the contralateral foreleg through axonal transport from the toxin-treated foreleg of rats.

Yasushi Torii1, Norio Akaike, Tetsuhiro Harakawa, Keiko Kato, Nakaba Sugimoto, Yoshitaka Goto, Shinji Nakahira, Tomoko Kohda, Shunji Kozaki, Ryuji Kaji, Akihiro Ginnaga.   

Abstract

The adverse effects of botulinum LL toxin and neurotoxin produced by subtype A1 (A1LL and A1NTX) are becoming issues, as the toxins could diffuse from the toxin-treated (ipsilateral) to contralateral muscles. We have attempted to produce neurotoxin from subtype A2 (A2NTX) with an amino acid sequence different from that of neurotoxin subtype A1. We measured the grip strength on the contralateral foreleg as an indicator of toxin spread from the ipsilateral to contralateral muscles. Doses of 0.30 log U or above of A1LL and A1NTX reduced the contralateral grip strength, whereas a dose of 0.78 log U of A2NTX was required to do so. We investigated the route of toxin spread using denervated, colchicine-treated, and antitoxin-treated rats. A1LL was transported via axons at doses higher than 0.30 log U and via both axons and body fluid at about 0.80 log U or a higher dose. Interestingly, A2NTX was transported via body fluid at about 0.80 log U or a higher dose, but not via axons to the contralateral side. It was concluded that A1LL and A1NTX decreased the grip strength of the toxin-untreated foreleg via both axonal transport and body fluids, while A2NTX was only transported via the body fluid.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22123262     DOI: 10.1254/jphs.11121fp

Source DB:  PubMed          Journal:  J Pharmacol Sci        ISSN: 1347-8613            Impact factor:   3.337


  17 in total

1.  Entry of Botulinum Neurotoxin Subtypes A1 and A2 into Neurons.

Authors:  Abby R Kroken; Faith C Blum; Madison Zuverink; Joseph T Barbieri
Journal:  Infect Immun       Date:  2016-12-29       Impact factor: 3.441

2.  Botulinum toxin B in the sensory afferent: transmitter release, spinal activation, and pain behavior.

Authors:  Marc J Marino; Tetsuji Terashima; Joanne J Steinauer; Kelly A Eddinger; Tony L Yaksh; Qinghao Xu
Journal:  Pain       Date:  2013-12-11       Impact factor: 6.961

3.  Comparative functional analysis of mice after local injection with botulinum neurotoxin A1, A2, A6, and B1 by catwalk analysis.

Authors:  Molly S Moritz; William H Tepp; Heather N'te Inzalaco; Eric A Johnson; Sabine Pellett
Journal:  Toxicon       Date:  2019-06-07       Impact factor: 3.033

4.  In vivo onset and duration of action varies for botulinum neurotoxin A subtypes 1-5.

Authors:  Sabine Pellett; William H Tepp; Regina C M Whitemarsh; Marite Bradshaw; Eric A Johnson
Journal:  Toxicon       Date:  2015-06-27       Impact factor: 3.033

Review 5.  Therapeutic use of botulinum toxin in migraine: mechanisms of action.

Authors:  Roshni Ramachandran; Tony L Yaksh
Journal:  Br J Pharmacol       Date:  2014-09       Impact factor: 8.739

6.  Thread lifting: a minimally invasive surgical technique for long-standing facial paralysis.

Authors:  W J Choe; H D Kim; B H Han; J Kim
Journal:  HNO       Date:  2017-11       Impact factor: 1.284

7.  Beyond muscular effects: depression of spinal recurrent inhibition after botulinum neurotoxin A.

Authors:  Véronique Marchand-Pauvert; Claire Aymard; Louis-Solal Giboin; Federica Dominici; Alessandro Rossi; Riccardo Mazzocchio
Journal:  J Physiol       Date:  2012-10-08       Impact factor: 5.182

8.  Transsynaptic inhibition of spinal transmission by A2 botulinum toxin.

Authors:  Norio Akaike; Min-Chul Shin; Masahito Wakita; Yasushi Torii; Tetsuhiro Harakawa; Akihiro Ginnaga; Keiko Kato; Ryuji Kaji; Shunji Kozaki
Journal:  J Physiol       Date:  2012-10-29       Impact factor: 5.182

9.  Characterization of botulinum neurotoxin A subtypes 1 through 5 by investigation of activities in mice, in neuronal cell cultures, and in vitro.

Authors:  Regina C M Whitemarsh; William H Tepp; Marite Bradshaw; Guangyun Lin; Christina L Pier; Jacob M Scherf; Eric A Johnson; Sabine Pellett
Journal:  Infect Immun       Date:  2013-08-05       Impact factor: 3.441

Review 10.  Current status and future directions of botulinum neurotoxins for targeting pain processing.

Authors:  Sabine Pellett; Tony L Yaksh; Roshni Ramachandran
Journal:  Toxins (Basel)       Date:  2015-11-04       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.